Outcome of AGM
Venus Remedies Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on September 30, 2011, inter alia, have accorded to the following:1. Adoption of Balance Sheet as on March 31, 2011 and Profit & Loss Account for the year ended on that date along with Report of directors and Auditors report thereon.... Venus Remedies' anti cancer product DOCETAXEL receives market authorisation in Europe
Venus Remedies Ltd has informed BSE that Venus Remedies' anti cancer product DOCETAXEL receives market authorisation in Europe.Announcement:"The Company has received one more Market Authorisation (MA) for its anti cancer product, DOCETAXEL. The Company's wholly-owned subsidiary, Venus Pharma GmbH, Germany has received this MA for Portugal. The Company is all set to launch this anti-cancer drug in this market by end of 2011 and it has also filed a patent for this product.... Outcome of Board Meeting
Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 24, 2011, inter alia, has approved the following;1. Issue of fully convertible warrants on a preferential basis to Sunev Pharma Solutions Ltd., a promoter group company upto 5% of the total capital in a financial Year in accordance with SEBI (Substantial Acquisitions and Takeovers) Regulations, 1997. The same is also subject to applicable... Board Meeting on Aug 24, 2011
Venus Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 24, 2011, inter alia, to consider and approve the following;1. Issue of fully convertible warrants to promoters/persons acting in concert on a preferential basis subject to approval of the general meeting.2. Allotment of equity shares pursuant to request of FCCB holders for partly conversion of Foreign Currency Convertible Bonds. Venus Remedies' novel research product 'Vancoplus' receives US PATENT
Venus Remedies Ltd has informed BSE that Venus Remedies' novel research product 'Vancoplus' receives US PATENT.Announcement:"The Company has received its first US patent from US PTO for its novel research product, Vancoplus. With this patent grant, which is valid up to December 2027, the Company is all set to tap the US market by launching the product. earlier, Vancoplus has already been granted the patents from countries like South Africa, New Zealand and Ukraine.... Fixes Book Closure for Dividend & AGM
Venus Remedies Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 25, 2011 to September 30, 2011 (both days inclusive) for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on September 30, 2011. Board recommends Dividend
Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 26, 2011, inter alia, has recommended a dividend @ of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2011 subject to approval of the same by shareholders at the Annual General Meeting. Financial Results for June 30, 2011
Venus Remedies Ltd has informed BSE about the Financial Results for the period ended June 30, 2011. Audited Financial Results for Mar 31, 2011
Venus Remedies Ltd has informed BSE about the Audited Financial Results for the period ended March 31, 2011. Board to consider Dividend
Venus Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 26, 2011, inter alia, to consider and approve the following;1. Unaudited Financial Results (Provisional) for the quarter ended June 30, 2011.2. Annual Accounts of the Company for the year ended March 31, 2011.3. Recommendation of dividend for the year 2010-2011.4. Fix the Date of Annual General Meeting.